×
BioVie Price/Book Ratio 2013-2024 | BIVI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
BioVie price/book ratio from 2013 to 2024. Price/book ratio can be defined as
View More
BioVie Price/Book Ratio 2013-2024 | BIVI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
BioVie price/book ratio from 2013 to 2024. Price/book ratio can be defined as
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$88.3B
Takeda Pharmaceutical (TAK)
$46.6B
Merck (MKGAF)
$23B
Astellas Pharma (ALPMY)
$21.6B
Sandoz Group AG (SDZNY)
$18.1B
Summit Therapeutics (SMMT)
$16.5B
United Therapeutics (UTHR)
$15.9B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$11.7B
Catalent (CTLT)
$10.9B
Orion OYJ (ORINY)
$7.7B
Revolution Medicines (RVMD)
$7.3B
Jazz Pharmaceuticals (JAZZ)
$6.8B
Ionis Pharmaceuticals (IONS)
$6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$4.6B
Corcept Therapeutics (CORT)
$4.5B
Crinetics Pharmaceuticals (CRNX)
$4B
Dyne Therapeutics (DYN)
$3.5B
PTC Therapeutics (PTCT)
$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Arrowhead Pharmaceuticals (ARWR)
$2.4B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Recursion Pharmaceuticals (RXRX)
$2B
Soleno Therapeutics (SLNO)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Xencor (XNCR)
$1.6B
Harrow (HROW)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Cassava Sciences (SAVA)
$1.5B